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BACKGROUND: Historically the success of mass spectrom-
etry in the clinical laboratory has focused on drugs of
abuse confirmations, newborn screening, and steroid
analysis. Clinical applications of mass spectrometry con-
tinue to expand, and mass spectrometry is now being
used in almost all areas of laboratory medicine.
CONTENT: A brief background of the evolution of mass
spectrometry in the clinical laboratory is provided with a
discussion of future applications. Prominent examples of
mass spectrometry are covered to illustrate how it has
improved the practice of medicine and enabled physi-
cians to provide better patient care. With increasing eco-
nomic pressures and decreasing laboratory test reim-
bursement, mass spectrometry testing has been shown to
provide cost-effective solutions. In addition to pointing
out the numerous benefits, the challenges of implement-
ing mass spectrometry in the clinical laboratory are also
covered.
SUMMARY: Mass spectrometry continues to play a prom-
inent role in the field of laboratory medicine. The ad-
vancement of this technology along with the develop-
ment of new applications will only accelerate the
incorporation of mass spectrometry into more areas of
medicine.
© 2015 American Association for Clinical Chemistry
Mass spectrometry (MS)3 provides unique capabilities in
the clinical laboratory and is rapidly transitioning from
specialized testing to being broadly applied. Historically,
major impacts of MS include confirmation of
immunoassay-positive drug screens (1 ), identification of
inborn errors of metabolism (2 ), and analysis of steroid
hormones (3 ). More recently, MS has dramatically im-
proved the time required for microbial identifications
(4 ). This evolution, driven by continuous improvements
in analytical platforms, is anchored by the analytical spec-
ificity of MS. Conclusive identification of molecules that
range in size from tens of daltons (small molecules) to
hundreds of thousands of daltons (biomolecules) is based
on different principles. For example, small molecules
are currently identified using LC-MS/MS. LC-MS/MS
identifications are based on several unique characteristics,
including retention time, parent ion, and ratios of frag-
ment ions. In the case of newborn screening, samples are
directly infused into the mass spectrometer with identi-
fications based on specific transitions of precursor and
product ions. In the microbiology laboratory, identifica-
tions are based on patterns of ions generated frommicro-
bial proteins ionized by laser ablation. In all cases, the
analytical specificity of the analysis is based on the ability
of a mass spectrometer to “weigh on the molecular scale”
by determining the mass-to-charge ratio (m/z) of the ions
of interest. In the simplest form, MS provides some type
of a molecular fingerprint of the analyte of interest. This
minireview provides a brief background on the evolution
of MS in the clinical laboratory (Fig. 1) and summarizes
how MS is being used to improve patient care in a cost-
effective manner.
A major impetus that moved MS from the research
laboratory to the clinical laboratory was the accident on
the aircraft carrier Nimitz. On May 26, 1981, an aircraft
crashed while landing on the Nimitz, killing 14 and in-
juring 45 (5 ). Subsequent immunoassay tests demon-
strated that a large percentage of urine samples from ser-
vicemen were positive for marijuana metabolites. This
prompted President Reagan to develop a zero tolerance
for drugs of abuse in the military (6 ). Due to a large
number of false-positive immunoassay results, antibody-
based drug screens began to be considered “presumptive”
until confirmed byGC-MS (7 ). It was clear that the early
use of drug testing was effective at reducing the number
of positive employee drug test results, because positive
rates dropped from 18% to 8% over a 10-year time span
(8 ). Several studies also demonstrated that urine drug
testing was cost-effective (8, 9 ). The requirement for
GC-MS confirmation drove the development of MS in
toxicology laboratories, where it also began to be used for
therapeutic drug monitoring.
As the clinical laboratory became more familiar
with GC-MS, the limitation of immunoassays for ste-
roids became evident, especially when measuring low
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concentrations of testosterone in women and children
(3, 10 ). A primary limitation of GC-MS was that ana-
lytes needed to be volatile and thus most clinical assays
required multiple extraction/purification steps along
with a chemical derivatization to render the analytes
sufficiently volatile for analysis. The extensive sample
preparation schemes required for GC-MS analysis lim-
ited the widespread application of MS in the clinical
laboratory because of low throughput and high cost.
Atmospheric pressure ionization techniques such as
electrospray ionization (ESI) combined with high-
performance LC-MS/MS were the next major analyt-
ical improvements that enabled MS as a viable plat-
form for routine clinical laboratories.
ESI LC-MS/MS eliminated the need for volatile
analytes and thus helped simplify sample preparation
schemes. Simplified sample preparation equates to im-
proved sample throughput and lower costs. GC-MS as-
says that took a technologist 8 h to prepare 50 samples
could now be done by the same technologist at much
higher throughput in a couple of hours when using LC-
MS/MS. The rate-limiting step for GC-MS analysis has
been the sample preparation time, whereas the rate-
limiting step in LC-MS/MS typically is the LC run time
of the assay. By simplifying sample preparation schemes
LC-MS/MS has enabledMS to be a cost-effective analyt-
ical tool in the clinical laboratory.
A particularly effective tool for improving through-
put of MS has been the development of multiplex assays
(11 ). From an initial capital outlay perspective, the mass
spectrometer is the highest-cost component (typically
$200 000 to $500 000). By interfacing several (com-
monly 2–4) LC systems (which cost $50 000 each) into
a single MS, the cost-effectiveness of the entire process
can be improved several fold. Multiplex LC works best
for single-analyte assays for which the injections of the
different LC systems are staggered so that the mass spec-
trometer is always measuring peaks of interest (Fig. 2). It
can also be used to analyze different compounds, poten-
tially enabling the technique to be applied in a random
access mode as opposed to more traditional batch analy-
sis. The basic principle that makes multiplexing effective
is that peaks of interest typically elute over a several sec-
ond time period during a chromatographic run, which
can last several minutes. Without multiplexing, most of
the time the mass spectrometer is “waiting” for peaks to
elute. By staggering injections, a multiplex with 4 LC
systems can increase the productivity of the MS several
fold.
In the microbiology laboratory, the development of
MALDI combined with TOF mass analyzers allowed for
the rapid identification analysis of microbes (12 ). Before
implementation of MALDI-TOF, microbiology labora-
tories depended on gram stain, culture, biochemical tests,
and susceptibility testing. US Food and Drug Adminis-
tration (FDA)-approved approaches using MALDI-
TOF have decreased the mean time to identification by
1.45 days compared with conventional techniques (13 ).
Tan et al. estimated that implementing MALDI-TOF
would save more than 50% of the costs of reagents and
labor compared with standard culture techniques (13 ).
These authors reported on the laboratory savings, but did
not comment on the overall healthcare savings associated
with rapid pathogen identification, which likely are sub-
stantial. The commercialization of MALDI-TOF con-
tinues for clinical microbiology and systems consisting of
the MS, software, and databases of microorganisms by
some manufacturers (bioMerieux Inc. and Bruker Dal-
tonics Inc.) have been FDA cleared. Although the FDA-
cleared list of organisms is not exhaustive and is primarily
limited to gram-negative and gram-positive bacteria and
yeast, research use–only libraries are also available (14 ).
Fig. 1. Approximate timeline of some important events in the evolution of clinical MS.
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As a result, users may need to build their own mass spec-
tral databases using locally isolated and relevant strains
that can then be searched along with the commercial
databases. For example, the Mayo Clinic has built a cus-
tom MALDI-TOF library that contains 1599 spectral
images not covered by available databases (14 ). However,
MALDI-TOF may not be the best technology for all
identifications because other technologies, like 16S
rRNA gene sequencing, may be better at rapidly identi-
fying tiny or mucoid colonies (14 ). Furthermore, newer
MS methods may also be superior at separating organ-
isms down to subspecies taxonomic levels (15 ). In addi-
tion to MALDI-TOF, other MS-based platforms for the
rapid identification of microbes directly from biological
samples have been developed. These platforms use ESI to
identify PCR products amplified using generic primers
(16 ). While not currently FDA approved, this approach
combines molecular specificity with an 8-h time to
identification.
Other novel applications of MALDI MS include
clinical imaging applications. In pathology research
and practice, MALDI imaging has been used to iden-
tify proteins, peptides, drugs or metabolites, lipids,
and other analytes in tissue (17 ). Specifically, MALDI
imaging has allowed the label-free, multiplex measure-
ment of a wide variety of molecules in tissue sections
while preserving the sample for conventional histology
staining. This combined approach keeps the spatial
localization of the resolved mass spectra, and the soft-
ware can be used to provide a virtual microdissection
of the tissue while visualizing individual molecules or
groups of molecules. MALDI imaging studies have
already been performed using fresh-frozen, paraffin-
embedded, and formalin-fixed tissues (18 ). A recent
MALDI imaging study was able to show de novo iden-
tification and characterization of phenotypic tumor
subpopulations that correlated to survival prognosis
without any prior molecular knowledge about the tu-
mor (17, 19 ). Identification of spatially resolved mol-
ecules by direct mass measurement and alignment to
databases can be done by high-mass accuracy MALDI
imaging technologies. This information may help gen-
erate a more complete understanding of diseases and
pathophysiology (20 ).
Metabolomic, lipidomic, and proteomic, as well as
other omic analyses of clinical samples using MS, is an-
other exciting area of research that may have broad im-
plications for the clinical laboratory. The goal of these
techniques is to capture information on several biomol-
ecules using a targeted approach (21, 22 ) to hundreds or
thousands of compounds using an untargeted approach
(23 ). The untargeted approaches are generally used in
the discovery phase to compare omic samples from 2
different populations (e.g., healthy and diseased). Once
molecules that differentiate the 2 populations have been
identified, a targeted approach can be used to further
characterize the utility of monitoring changes in the pu-
tative biomarkers. One particularly novel approach to
metabolomics is the use of stable isotopes to trace meta-
bolic fate of energy sources in diseased and healthy cells
(24 ).
Advantages of MS
MSis slowly transforming thepracticeof laboratorymedi-
cine and is being driven by several factors, including im-
proved analytical specificity and sensitivity. Measure-
ments of testosterone and other sex steroids have been
used as examples for which MS is the preferred method.
Professional society guidelines (e.g., originally endocri-
nology and currently urology) requiring the use of MS
help propagate this transition (25, 26 ). The measure-
ment of testosterone in children and adults of both sexes
is important in the diagnosis and management of numer-
ous conditions (e.g., infertility, certain cancers, viriliza-
tion, and polycystic ovary syndrome) (27, 28 ). Although
Fig. 2. Multiplex LC-MS system.
In this example, 4 LC systems are connected to one mass spec-
trometer via a multiposition switching valve. Peaks indicate the
compound of interest. Solid bars indicate which LC system is in-
terfacedwith theMS in time. For LC 1 the peak of interest elutes at
0.5 min, yet the total LC run is 1.25 min due to factors such as
column re-equilibration or injector cycle time. The injection of the
LC systems is set so that LC 2 injects 0.25 min after the first sam-
ple. After the peak from LC 1 elutes, the valve switches so that LC 2
is now in linewith themass spectrometer. This is repeated for all 4
LC systems. In this fashion, the mass spectrometer is always col-
lecting data when peaks of interest are eluting, increasing the
efficiency of the system.
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manual RIAs were originally used owing to their analyt-
ical sensitivity, automated immunoassays soon replaced
them for improved throughput and the desire to elimi-
nate radioactivity in the laboratory. However, these im-
munoassays suffered from analytical specificity problems
and a limited dynamicmeasuring range (26 ). Traditional
immunoassays were shown to significantly overestimate
testosterone concentrations in women and slightly un-
derestimate testosterone in men (3, 10 ). On the other
hand, MS-based methods have been shown to have su-
perior analytical specificity and the ability to measure
testosterone over a wide concentration range required for
children and adults of both sexes (27 ).
The measurement of thyroglobulin is another clinical
example for which MS has been shown to offer superior
assay quality compared to traditional immunoassays. Thy-
roglobulin is used to evaluate the effectiveness of treatment
and the reoccurrence of thyroid cancer. However, im-
munoassays can be affected by antithyroglobulin au-
toantibodies, resulting in falsely low thyroglobulin
measurements (29 ). Using tryptic digestion with
peptide-specific immunocapture, LC-MS/MS quanti-
fication of the thyroglobulin-specific peptides is able
to overcome the interference of antithyroglobulin au-
toantibodies (29, 30 ). The MS-based method is also
thought to overcome interferences due to heterophilic
antibodies that can cause falsely increased thyroglob-
ulin measurements in immunoassays (31 ).
Cost reduction is another pressuredriving the adoption
of MS. Although the initial capital cost of the equipment is
high and laboratory expertise in the development, valida-
tion, andmaintenance ofMS-based assaysmaybe limited, it
still can be cost-effective for laboratories to developMS tests
to avoid send-out costs on higher-volume tests. In addition,
the ability to develop multianalyte panels using a singleMS
method offers additional time, labor, and expense savings,
for which immunosuppressant assays are a great example.
Clinical laboratories started to use LC-MS/MS to simulta-
neously measure cyclosporine A, tacrolimus, sirolimus, and
everolimus. The simplified and standardized sample pro-
cessing of a panel of drugs saves time, reagents, and labor
expenses. The analytical specificity of MS-based immuno-
suppressant assays is also superior to that of existing immu-
noassays, which can overestimate the concentration of these
medications because of the variable cross-reactivity with
immunosuppressant metabolites (32–34). Lastly, there is
now one FDA-approved MS tacrolimus assay (Waters-
MassTrak®) and several commercially available MS kits
with IVD (in vitro diagnostic)-CE certification for the
measurement of immunosuppressants (Chromsystems-
MassTox®, Recipe-ClinMass®, andWaters-MassTrak®),
which make MS-based assays more attractive for smaller
laboratories with less expertise (35).
Challenges with MS
Although MS continues to make significant contribu-
tions to patient care, there are substantial challenges that
need to be understood before implementing an MS-
based service. These challenges include the high capital
cost of equipment, requirements for a skilled labor force,
lack of automation, and regulatory uncertainty.
The high capital cost of equipment is straightfor-
ward to deal with using routine return on investment
calculations. When considering MS, laboratories need to
account for instrument costs, labor and training costs,
proficiency testing, reagents, supplies, service contracts,
and construction/renovation costs that may be required
for installation of this type of instrumentation. In addi-
tion, the time and expense to support assay development
and validation need to be accounted for. Instruments
typically deployed in clinical laboratories cost between
$200 000 and $500 000 but can be justified by incorpo-
rating expensive or high-volume send-out tests into the
laboratories’ offerings. Send-out tests are a financial loss
for laboratories because Medicare prevents laboratories
from billing more than what the reference laboratories
charge. These send-out tests create a large deficit because
most laboratories recoup only about 25% of the billed
cost. For example, if your laboratory (laboratory A) sends
a test to reference laboratory B, and laboratory B bills you
$100, laboratory A is obligated to pay the full fee. Labo-
ratory A then passes this $100 fee on to the patient’s
insurance company, which has an agreement with labo-
ratory A’s hospital that it pays only 25% of fees. This
simple transaction costs the hospital $75 each time the
test is sent out (not including costs associated with the
send-out process). If you offer this same test in house you
can bill appropriately and turn this loss into a potential
profit. MS also provides the ability to expand the test
menu more quickly for novel biomarkers instead of wait-
ing for FDA-approved kits/assays.
Justification of MS can also be achieved by looking
at existing in-house tests. Laboratories are always looking
for ways to reduce or remove radioactivity (i.e., RIAs)
from the laboratory due to safety and regulatory issues.
MS offers a cost-effective alternative to measure tradi-
tional RIA-measured analytes like free testosterone,
insulin, prolactin, and 1,25-dihydroxyvitamin D. Alter-
natively, the cost of some traditional, lower-volume im-
munoassays like C-peptide or -hydroxybutyrate, which
may exceed $20/test on commercial platforms, can be
done for substantially less by MS while providing supe-
rior results. Recently, the cross-reactivity of 10 different
immunoassays with 15 exogenous insulins was examined
and the authors concluded that, due to the poor cross-
reactivity of the immunoassays, MS should be used to
diagnose hypoglycemia secondary to exogenous insulin
(36 ). Although any single assay may not be enough to
Effective Use of MS in the Clinical Lab Reviews
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justify the costs of a mass spectrometer and all the re-
quired laboratory renovations, development, validation,
training, and labor, combinations of multiple in-house
and/or send-out tests can be used to successfully justify
the acquisition of this technology.
Another challenge with setting up an MS-based lab-
oratory service is deciding what instrumentation to pur-
chase. The choice of instrumentation depends on the
analytes of interest. Formost small-molecule quantitative
methods (e.g., testosterone, vitamin D, drugs of abuse)
a triple-quadrupole mass spectrometer with LC is the
instrument of choice. Triple-quadrupole mass spectrom-
eters are also used for newborn screening and for quanti-
fication of peptides and proteins. For a clinical microbi-
ology laboratory interested in qualitative identification of
a variety of microbes, a MALDI-TOFmass spectrometer
is optimal. Although new developments such as high-
resolution MS offer tantalizing potential for improve-
ment, existing instrumentation that has a proven track
record in the clinical laboratory is a reasonable place to
start. As has been pointed out, users of MS tend to think
that the next analytical advance is a cure all, when most
improvements are incremental (37 ).
Traditionally, MS analysis is also more efficiently
used when run in batch mode analysis. Although assays
can be developed that use similar columns/mobile
phases, the systems aren’t completely random access and
users can face challenges when needing to shift between
positive/negative mode, column temperature, and mo-
bile phases. In addition, one of the main factors that
currently drive batch mode analysis is that the sample
preparation (extraction/purification/processing) re-
quired before MS analysis is most efficiently per-
formed in batches.
The requirement for skilled labor is especially acute
for MS applications based on laboratory-developed tests
(LDTs). LDTs require considerable expertise in method
development and validation. These talents are difficult to
acquire in a training environment and generally require
several years of practical experience in a functional MS
laboratory to become proficient. It is interesting to note
that for the microbiology laboratory, MS has been suffi-
ciently simplified so that MS expertise is not required to
run and maintain the instrumentation. For clinical mi-
crobiology, MS is simply a read-out device. For MS to
become broadly used in the clinical laboratory, more
FDA-approvedMS-based platforms and NIST-traceable
assay kits, calibrators, QCs, and infusion standards need
to be commercially available. Nowadays, many clinical
laboratories have shifted to commercially prepared re-
agents, QCs, and calibrators, so laboratory technologists
have become less familiar and adept at calculating, weigh-
ing out, and/or preparing these items. Lastly, arguments
can be made that most of the technologists running so-
phisticated high-throughput chemistry analyzers don’t
understand how a select wavelength is used tomonitor an
endpoint reaction. Likewise, until MS becomes “just an-
other detector” on an automated FDA approved plat-
form, the full benefit of the technology will not be
realized.
Another challenge facing laboratories is the lack of a
seamless automated solution incorporating sample han-
dling, processing, and preparation through analysis with
direct bidirectional interfacing with the instrumentation
to the laboratory information system (LIS). Currently,
stand-alone components exist that can automate sample
preparation/processing, but they operate independently
of the LC-MS/MS system. There is a lack of a commer-
cial middleware or other software solution to coordinate
and control all the equipment and to bidirectionally
communicate between the LIS and the MS. One module
to track sample location, tests required, control sample
processing, test analysis, and transfer of the results di-
rectly back to the LIS like other fully automated chemis-
try solutions is needed. Often laboratories have to export
results from the MS and use Excel macros to perform
calculations or reporting rules before getting the results
into the LIS. Manual result entry is also not practical on
high-volume tests and is prone to high error rates and
labor costs.
The widespread clinical use of MS for various omics
technologies faces several challenges as the technology
moves from research applications comparing different
populations to the diagnosis and treatment of individual
patients. Earlier we listed the proteomic analysis of thy-
roglobulin as an area where MS can offer clinical benefit
compared with immunoassay, due to the interference of
autoantibodies. Unfortunately, MS does not provide all
the needed answers in these cases because there are re-
ports of image-confirmed disease recurrence that had un-
detectable concentrations of thyroglobulin by MS (38 ).
A closer examination of the technology reveals that many
variables need to be controlled to provide an accurate
quantitative result. These analytical challenges are sub-
stantial and similar to those with other omic approaches.
As we move these applications from research laboratories
into clinical practice, a host of infrastructure also needs to
be developed, including reference materials, reference
methods, and proficiency testing programs. In addition,
laboratories will need regulatory guidance to design ap-
propriate quality assurance and QC programs. New lab-
oratory inspection protocols will also need to be devel-
oped, vetted, and implemented.
Lastly, the FDA released draft guidelines for regula-
tion of LDTs on Oct 3, 2014, but it is unclear when the
final guidelines will be issued and how long they will take
to implement (39 ). The draft document makes clear that
the FDA will pursue a risk-based management strategy
and that the prototypical MS-based LDT developed and
offered within a single hospital setting will be low or
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moderate risk (class 1 or 2 medical devices). The FDA
will clarify classification of risk 24 months after the final
guidance documents are published, but at present the
time frame for release of the final guidance is unclear. Six
months after the final LDT regulatory guidance is pub-
lished all laboratories that perform LDTs will be required
to register with the FDA. However, class 1 and class 2
medical devices (traditional MS based LDTs) will not
have to apply for premarket approval until 5 years after
the final guidance is issued, and the registration process
will be phased in over the subsequent 4 years. From a
near-term practical aspect, laboratories investing in MS
should know if the instrument they are considering is
FDA approved as a diagnostic device, but it appears that
formal regulation of traditionalMS based LDTs is at least
5 years in the future.
Future Applications
New horizons and trends indicate a bright future for MS
in laboratory medicine. The miniaturization of MS sys-
tems being pursued at places such as Purdue University
could allow a transportable device that minimizes the
specialized skill set required for operators and allows for
rapid and accurate MS analysis in a point-of-care format.
These devices could be used in various settings (e.g., phy-
sician offices), but this appears to be some time from
implementation (40 ). Presently, MS is already being
used outside of the clinical laboratory in the operating
rooms at the Imperial College in London, where the sur-
geon’s knife is connected to a mass spectrometer to dif-
ferentiate between normal and cancerous tissue (41 ). Ad-
ditional areas where MS is expanding include the field of
proteomics and protein panels. Immunoglobulins can
now be measured by MS and are viewed as important
biomarkers for immunity, autoimmunity, cancer detec-
tion, and immune system function (42 ). Monoclonal
antibodies are also being used as therapeutic agents for a
wide variety of diseases. For example, infliximab is used
to treat Crohn disease and ulcerative colitis, and thera-
peutic concentrations are associated with clinical re-
sponse and improved prognosis. MS-based methods
could overcome the interference seen with endogenous
autoantibodies directed against infliximab that is present
in the existing immunoassays used to measure these
compounds.
Laboratories are also looking to connect MS-based
systems to fully automated chemistry lines and integrate
them directly to the LIS. In addition, MS vendors are
working on more ready-to-use “FDA-approved” reagent
kits for MS to help diminish barriers for clinical labora-
tories to adopt this technology. This trend will ultimately
result in the introduction of a fully automated clinical
chemistry analyzer that incorporates a mass spectrometer
as the detector. Further improvements in analytical sen-
sitivity and specificity, automated sample preparation,
and throughput will allow more clinical applications to
adapt this technology.MS-basedmethods are an essential
component of diagnostic medicine and will continue to
grow in scope as regulatory, analytical, and personnel
challenges are solved.
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